8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 3, 2014 (February 27, 2014)

 

 

ARCA biopharma, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   000-22873   36-3855489

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

11080 CirclePoint Road, Suite 140, Westminster, CO 80020

(Address of Principal Executive Offices) (Zip Code)

(720) 940-2200

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Bonuses, Base Salaries and Equity Grants

On February 27, 2014, the Compensation Committee (the “Committee”) of the Board of Directors of ARCA biopharma, Inc. (the “Company”), approved cash bonuses (the “Bonuses”) for each of the executive officers of the Company in the amounts set forth below, payable on or around March 7, 2014. The Committee also approved the base salaries for the Company’s “named executive officers” (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission), in each case as set forth below.

 

Name and Title

   2014
Cash Bonus
     Base Salary  

Michael R. Bristow

President and Chief Executive Officer

   $ 60,050       $ 281,139   

Patrick M. Wheeler

Chief Financial Officer

   $ 46,650       $ 268,975   

Christopher D. Ozeroff

Senior Vice President, General Counsel

   $ 35,200       $ 274,773   

The Committee determined the Bonuses are to be paid in recognition of the past efforts of each of the executives. The new base salaries will become effective on March 1, 2014.

On February 27, 2014, the Compensation Committee also approved the following stock option (“Options”) and restricted stock unit (“RSUs”) grants to the below executive officers pursuant to the Company’s 2013 Equity Incentive Plan and the forms of Stock Option Grant Notice, Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement for officers, as filed with the Securities and Exchange Commission as exhibits to the Company’s Current Report on Form 8-K on September 23, 2013:

 

Name

   Options Granted (1)      RSU’s Granted (2)  

Michael Bristow

President and Chief Executive Officer

     51,500         56,700   

Christopher Ozeroff

Senior Vice President, General Counsel & Secretary

     10,500         34,200   

Patrick Wheeler

Chief Financial Officer

     20,500         34,200   

 

(1) Vests in 48 equal monthly installments measured from February 27, 2014
(2) Vests in 4 equal annual installments measured from February 27, 2014


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 3, 2014

 

ARCA biopharma, Inc.

(Registrant)

By:   /s/ Patrick M. Wheeler
  Name: Patrick M. Wheeler
  Title: Chief Financial Officer